CRISPR-Cas13 has rapidly become one of the most versatile tools in plant biotechnology, offering researchers the ability to ...

On September 23, 2026, Anthropic announced that "Claude discovered a previously unknown enzyme mechanism within viral DNA" ...

A new review maps how bacterial anti-phage defenses, from restriction enzymes to Thoeris and CBASS immune signaling, shape ...

What you will learn in this article On September 23, 2026, Anthropic announced that Claude agents explored over 200,000 ...

Anthropic said its Claude AI model identified a previously uncharacterized enzyme system with repeating DNA patterns similar to CRISPR, marking ...

Claude AI biology discovery: Anthropic's Claude Mythos 5 agents autonomously searched 1.9 billion protein clusters and identified ART, a previously uncharacterized enzyme system in bacteriophage DNA ...

Anthropic's Claude found ART, an enzyme system with CRISPR-like repeat sequences. We examine the paper's experimental results ...

Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances.

A groundbreaking Phase 1 clinical trial conducted by Cleveland Clinic has unveiled promising results regarding a novel CRISPR ...

Anthropic’s claim its AI agents discovered an unusual pattern in viral DNA similar to what’s seen in the gene-editing tool ...

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

Experts at the company don't know what the newfound system does, so its potential utility in biology—if any—remains unclear.